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Introduction
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and is frequently associated with autism spectrum disorder (ASD) (McLennan et al., 2011) . In addition to cognitive impairment, individuals with FXS often exhibit seizures and autistic behaviours as well as attention deficits, social anxiety, obsessive-compulsive disorder, and stereotypic repetitive motions. Expansion of a CGG trinucleotide repeat within the 5'-UTR of the FMR1 gene, located on chromosome X, results in epigenetic silencing and loss of the fragile X mental retardation protein (FMRP) . FMRP binds to RNA and negatively regulates translation of $1400 mRNA targets (Brown et al., 2001; Miyashiro et al., 2003; Darnell et al., 2011) . It is highly expressed in neurons, where it plays a role in the regulation of dendritic spine morphology and synaptogenesis (Irwin et al., 2000; Huber et al., 2002) . The focus of FXS research has been mainly on the role of FMRP in neurons and its effects on synaptogenesis and circuit maturation.
In spite of a lack of direct experimental data, genomic analysis studies of autism suggest that molecular and network dysfunction in ASD may occur earlier in development than was previously thought. A list of genes known to be associated with ASD and ASD risk is maintained by The Simons Foundation Autism Research Initiative (SFARI) database. Many of the mutated or dysregulated genes in the SFARI database are FMRP targets (Iossifov et al., 2012; Parikshak et al., 2013) and genes implicated in ASD are often temporally co-expressed during human corticogenesis (Parikshak et al., 2013) . Furthermore, some ASD-associated genes are involved in cortical lamina specification and synaptic development during mid-gestation (Willsey et al., 2013) .
Due to an inaccessibility of human tissue, there have been few studies that have examined the role FMRP plays during human brain development and during the early developmental stages of FXS. Growing evidence demonstrates aspects of human development and disease can be accurately modelled in vitro using human pluripotent stem cells (hPSCs) (Passier et al., 2016) . Studies involving human FXS embryonic stem cell lines (derived from FXS embryos identified by pre-implantation diagnosis) have demonstrated neurodevelopmental and synaptic defects (Sheridan et al., 2011; Telias et al., 2013 Telias et al., , 2014 Telias et al., , 2015 Doers et al., 2014) and a wide variability in the timing of FMR1 epigenetic silencing during neuronal differentiation (Telias et al., 2013; Colak et al., 2014) . But the earlier stages of neurogenesis have not been examined.
Unlike most of the epigenome, the epigenetic marks that result in FMR1 silencing remain refractory to reprogramming (Urbach et al., 2010) . Although genome editing has been used to de-repress the silenced FMR1 locus in human induced pluripotent stem cells (hiPSCs) (Park et al., 2015) , hiPSCs derived from patients with FXS generally act as FMR1 knockouts. The goal of our study was to develop a map of the dynamic transcriptomic and epigenetic changes during neocorticogenesis in the presence and absence of FMR1 expression. We generated neuronal progenitor cells (NPCs) and neurons from hiPSCs derived from several male individuals clinically diagnosed with FXS and ASD. Examination of different temporal stages of neurogenesis revealed novel disease-specific defects that appear early in dorsal forebrain development. Global gene expression and DNA methylation profiling indicated that FXS cells exhibit defects in developmental signalling, extracellular matrix rearrangement, cell migration, and neuronal maturation.
Materials and methods

Human induced pluripotent stem cell derivation and maintenance
These studies were performed according to approved IRB guidelines, with patient or guardian consent, and approved under the University of California -San Diego Embryonic Stem Cell Research Oversight (ESCRO) committee application #130336ZO. Each FXS subject was evaluated for ASD at the Fragile X Research and Treatment Center (University of California, Davis) using the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic InterviewRevised (ADI-R). Specifically, each subject was evaluated and scored for (i) language and communications; (ii) reciprocal social interactions; and (iii) restrictive, repetitive, and stereotyped behaviours and interests.
Dermal biopsies were collected from five male subjects: four diagnosed with FXS and ASD (identified as Patients SC105, SC128, SC133, SC215), and one non-disease subject (Subject 713). All biopsies were dissociated using collagenase B, plated on fibronectin (10 mg/ml), and maintained in Dulbecco's modified Eagle medium (DMEM) + 10% foetal bovine serum (FBS), penicillin/streptomycin and primocin. Human dermal fibroblasts from Patients SC105 (passage 5), SC128 (passage 10), SC133 (passage 8), and 713 (passage 5) were transduced with pMX POU5F1(OCT4), SOX2, KLF4, and MYCL retroviral particles as previously described (Nazor et al., 2012) . Human dermal fibroblasts from Patient SC215 (passage 4) were transduced with Sendai virus (CytoTune iPS Sendai Reprogramming Kit, Invitrogen) using a 2:1 multiplicity of infection ratio of OCT4/KLF4 virus to SOX2/C-MYC virus, respectively. Colonies exhibiting hiPSC morphology were picked and expanded on mitotically-inactivated mouse embryonic fibroblasts in DMEM/F12, 20% knockout serum replacement (Life Technologies), GlutaMax TM (Life Technologies), MEM non-essential amino acids (Life Technologies), 0.1 mM 2-mercaptoethanol (Life Technologies), 12.5 ng/ml FGF2. HPSC lines were adapted to feeder-independent growth on Geltrex Õ (Life Technologies, 1:200 dilution) and maintained in TeSR-E8 medium (Stem Cell Technologies). Two hiPSC lines from each FXS patient (Patients SC128, SC1233, SC105 and SC215), the non-disease hiPSC line (Subject 713), and a non-disease hESC line (SAB1-13D, a kind gift from S. Fisher, UCSF) were used for profiling and differentiation. Together these lines (nine hiPSC and one hESC) comprise the 10 hPSC lines used in this study. hPSCs at 515 passages were used for profiling and differentiation experiments. All of the FXS hiPSC lines used in this study are available through the National Institute of Mental Health (NIMH) coordinated Rutgers University Cell and DNA Repository (RUCDR).
Single nucleotide polymorphism genotyping
All cell lines were single nucleotide polymorphism (SNP) genotyped at the Rutgers DNA and Cell Repository using the Fluidigm SNP Trace panel of 96-SNPs. DNA samples analysed from each cell line were the same Day 0 samples used for methylation profiling.
FMR1 characterization and FMRP immunoblotting
FMR1 CGG repeats were amplified from genomic DNA using the AmplideX Õ FMR1 PCR Kit (Asuragen) according to the manufacturer's instructions, followed by capillary electrophoresis for length determination. For FMR1 reverse transcription quantitative polymerase chain reaction (RT-qPCR), first-strand cDNA synthesis was performed using the QuantiTect Õ cDNA synthesis kit (Qiagen) and 200 ng total RNA. FMR1 and GAPDH were multiplex amplified with TaqMan Õ probes FAM-Hs00924547_m1 and VIC-Hs99999905_m1 (ABI, Life Technologies), respectively, on a CFX96 Real-Time System (Bio-Rad). FMR1 expression was normalized to GAPDH expression in each sample. Immunoblotting: whole cell extracts were prepared in RIPA buffer (1% NP-40, 0.5% deoxycholate, 1% SDS) with protease inhibitor cocktail (CalBiochem). Twenty micrograms of whole cell extract per line was subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (4-20%), transferred to nitrocellulose, and immunoblotted with antibodies against FMRP (Abcam ab17722, 1:200) and ACTB (b-actin) (Sigma, 1:10 000).
Neuronal differentiation
Human PSC lines were differentiated using dual SMAD inhibition using a modification of a published protocol (Chambers et al., 2009) . Specifically, high-density (480% confluence) feeder-independent hPSCs (two non-disease, four FXS FMR1 + and four FXS FMR1À) were induced to differentiate to NPCs in 20% KSR medium (without FGF2) containing 5 mM dorsomorphin (Stemgent) and 10 mM SB431542 (Stemgent). On differentiation Day 7, medium was changed to a 1:1 mixture of KSR medium and N2 medium [DMEM/F12, N2 supplement (Life Technologies), GlutaMax TM , MEM-NEAA] containing 5 mM dorsomorphin and 10 mM SB431542. On differentiation Day 9, medium was changed to 1:3 KSR:N2 medium, respectively, containing 5 mM dorsomorphin and 10 mM SB431542. On Day 11, medium was changed to N2 medium containing 5 mM dorsomorphin and 10 mM SB431542. To generate mature neurons, beginning at differentiation Day 13 cultures were maintained in maturation medium consisting of Neurobasal Õ medium (Life 
Electrophysiology
Coverslips containing D85-90 neuronal cultures from FXS FMR1 + (Patient SC128iPS2) and FXS FMR1À (Patient SC105iPS6) were placed in a perfusion chamber mounted on a Nikon Eclipse FN microscope. Spontaneous activity and evoked responses were recorded at 33 C under whole-cell conditions. The membrane potential and transmembrane current were measured using a MultiClamp700B amplifier (Molecular Devices) and sampled at 20 kHz using the data acquisition software DASYLab v.11 (National Instruments). Patch pipettes were pulled from standard borosilicate glass of 1.5 mm OD (Warner Instruments) and had input resistances of 6-8 M. The composition of the bath solution (artificial CSF) was: NaCl 125 mM, KCl 2.5 mM, CaCl 2 2 mM, MgCl 2 1 mM, NaH 2 PO 4 1.25 mM, NaHCO 3 26 mM, glucose 25 mM. For recording action potentials and voltage-gated currents, patch electrodes were filled with the following intracellular solution: K-gluconate 120 mM, KCl 10 mM, HEPES 10 mM, EGTA 10 mM, MgATP 2 mM, Na 3 GTP 0.3 mM; pH 7.3. To record voltage responses, we used incrementing levels of current steps of 350 ms duration. Neurons were stimulated with constant current steps starting from À50 pA and incremented by 5 pA up to a level of + 25 pA. Analysis of the evoked responses was performed using software developed by A. Szü cs (IVAnalyzer). A number of parameters including the resting membrane potential, rheobase, input resistance at rest, and spike amplitude were recorded. In voltage clamp experiments the cells membrane potential was held at À60 mV and spontaneous excitatory/inhibitory postsynaptic current were recorded at 20 kHz sampling rate. The amplitude threshold for EPSC detection was set to 3.4 pA below which events were not distinguishable from noise. Arrival time and amplitude of each EPSC event was determined and mean EPSC frequency and amplitude were calculated from recordings.
Gene expression profiling
Approximately 10 6 cells were used for each biological replicate. See Supplementary Fig. 1 Technologies) and quality (RNA6000 Nano Kit and Bioanalyzer 2100, Agilent) were quantified for each sample prior to further processing. Samples with RIN scores 5 9.0 were further processed. Two hundred nanograms of RNA per sample was amplified with the TotalPrep TM RNA Amplification Kit (Illumina) according to manufacturer's protocol, and quantified as above. Seven hundred and fifty nanograms of labelled RNA per sample was hybridized to HT-12v4 Expression BeadChips (Illumina) and scanned with an iScan (Illumina). In GenomeStudio, probes were filtered for those detected at P 5 0.01 in at least one sample and exported for robust spline normalization (RSN) in R using the lummi package.
PluriTest
To determine the pluripotent status of each cell line, global gene expression profiles were generated from each undifferentiated cell line using Illumina HT12v4 gene expression microarray as above. IDAT files from biological replicates were uploaded to www.pluritest.org.
DNA methylation profiling
Approximately 10 6 cells were used for each biological replicate. DNA was extracted using the DNeasy Õ kit (Qiagen) according to the manufacturer's recommendations and quantified using a Qubit Õ and dsDNA BR Reagent (Life Technologies).
Bisulphite conversion was performed using the EZ DNA Methylation TM Kit (Zymo Research) according to the manufacturer's instructions. Whole genome amplification, fragmentation, and preparation of the DNA for hybridization were performed using the Infinium HumanMethylation450 BeadChip kit (Illumina) as described in the manufacturer's protocol. Using the minfi Bioconductor package, Illumina IDATS were read directly into R and normalized using the Subset-quantile within array normalization (SWAN) for Infinium HumanMethylation450 BeadChips (Maksimovic et al., 2012) .
Autism spectrum disorder gene annotations
ASD-associated genes were downloaded from the Human Gene Module of the SFARI database (https://gene.sfari.org/ autdb/HG_Home.do) (Basu et al., 2009) . Of the 827 genes downloaded from the SFARI, we analysed 1090 probes for 707 SFARI genes using Ht12v4 Illumina Gene Expression Microarrays. Additionally, 1172 probes for 742 genes were annotated as being targets of FMRP according to (Darnell et al., 2011) . Supplementary Table 4 summarizes the SFARI and FMRP target gene lists.
Statistics Differential gene expression analysis
The time course neuronal differentiation data were analysed using limma (Smyth, 2004) . As described in Supplementary  Fig. 1 , cell lines were first grouped into three bins according to their specific characteristics of interest: (i) non-disease: two Early neurogenic deficits in FXS non-disease cell lines (expressing FMRP and lacking trinucleotide expansion); (ii) FMR1neg: four iPSC FXS FMR1À lines derived from Patients SC105 and SC215 (cell lines lacking FMRP expression); and (iii) FXS: the FXS FMR1À lines and four FXS FMR1 + iPSC lines derived from Patients SC128 and SC133 (cell lines carrying the FXS trinucleotide expansion in FMR1). In the first set of differential expression analyses, 'Contrasts 1-3', we set out to identify genes that were dynamic during differentiation within each of these three groups by identifying genes that had a fold-change 5 2.0 with a false discovery rate (FDR) 4 0.05 between successive differentiation stages (d0 versus d3, d3 versus d6,. . . d65 versus d80). The Benjamini and Hochberg procedure was used to calculate FDR-adjusted P-values for both differentially expressed genes and for differentially methylated cytosines (Reiner et al., 2003) . 'Contrast 4', identified which genes had significantly distinct patterned variation during differentiation between non-disease lines versus FMR1neg lines by identifying genes that had an FDR 4 0.05 [i.e. (FMR1neg.d0 versus FMR1neg.d3) versus (non-disease.d0 versus non-disease.d3)]. In addition to the above FDR cut-off, a probe was only called significant in Contrast 4 if there was at least a 1.5-fold difference between groups at the same differentiation stage [i.e. (FMR1neg_d0 versus non-disease_d0)]. Contrast 5 mirrored that of Contrast 4, with the FXS group used in place of the FMR1neg group in all comparisons. In the final set of contrasts, Contrasts 6-7, we set out to identify genes with static differences either between non-disease versus FMR1neg cell lines, or non-disease versus FXS cell lines. In this comparison, averages were calculated for all samples in a group, independent of differentiation stage, with significant comparisons called at a fold difference 5 1.5 and an FDR 4 0.05. Significant genes from Contrasts 4-7 were annotated as FXS GEX-Candidates. Complete commented code for the analysis of gene expression is included in the Supplementary material.
Differential methylation analysis
DNA methylation data were generated from biological replicate samples for all differentiation Day 0-12 samples analysed via gene expression and were analysed in an analogous manner. Probes were called significant in all contrasts at FDR (determined by the Benjamini and Hochberg procedure) 4 0.05 and the difference in b-values 4 0.25. Significant loci from Contrasts 4-7 were annotated as FXS differentially methylated cytosine (DMC) candidates. Complete commented code for the analysis of DNA methylation is included in the Supplementary material.
Weighted gene correlation network analysis
Weighted gene correlation network analysis (WGCNA) was performed in R using replicate level input data for both gene expression and DNA methylation. Briefly, 'signed' networks were constructed with minimum module sizes of 20 and 75 for gene expression and DNA methylation data, respectively. Probes were assigned to modules when R (probe:module eigengene) 5 0.5 at a significance level of P 4 0.05. Each probe was exclusively assigned to whichever module it was most highly and significantly correlated. Complete commented code for WGCNA analyses is included in the Supplementary material.
Functional enrichments
All functional enrichments were performed using the Genomic Regions Enrichment of Annotations Tool (GREAT) (McLean et al., 2010) using UCSC hg19 genome coordinates provided in Supplementary Table 5 . For gene expression, the initial set of 22 063 probes with detectable expression was used as 'Background Regions' and the 'Association Rule' was set to 'single nearest gene' including curated regulatory domains. Only enrichment terms with at least three input genes were reported. For DNA methylation, default Association Rule settings were used with the 'whole genome' option selected for Background Regions. Chi-squared contingency table tests were performed using the chisq.test function in the default 'stats' package in R. Complete commented code for all statistical analyses are provided in the Supplementary material.
Integration of DNA methylation and gene expression results
Gene expression probes were associated with individual methylated cytosine probes according to the default Association Rule settings in GREAT. Pearson correlations were calculated using data averaged by cell line and differentiation stage. Significant negative and positive correlations were called via identification of inflection points in the trimodal distribution of calculated correlation values, with significant negative correlations at R 4 À0.36 and significant positive correlations at R 5 0.37.
Results
Generation and characterization of FXS human induced pluripotent stem cell lines
HiPSCs were derived from four males clinically diagnosed with FXS and ASD at the Fragile X Research and Treatment Center (MIND Institute, University of California, Davis) using the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview -Revised (ADI-R). Detailed patient information as well as ADOS and ADI-R scores for each subject are listed in Supplementary Table 1 . Because FXS is an X-linked disorder, we used male hiPSCs to avoid potential problems associated with erosion of Xchromosome inactivation resulting in unbalanced X-linked gene dosage in female hPSCs (Mekhoubad et al., 2012; Nazor et al., 2012) .
In this study we compared two hiPSC lines from each of the four FXS patients (Patients SC105, SC128, SC133, and SC215) to a hiPSC line generated from a 'normal' male (Subject 713) and a male human embryonic stem cell (hESC) line (SAB1-13D), which are referred to as non-disease hPSC lines. Figure 1A lists the 10 cell lines used in this study. Each undifferentiated line was determined to be pluripotent based on global gene expression signatures when compared to other established hPSC lines (Muller et al., 2011) (Supplementary Fig. 2A ). Furthermore, each hPSC line was genetically barcoded by SNP genotyping (Supplementary Table 2 ).
FMR1 CGG repeat length is mosaic in cell populations from FXS patients (Nolin et al., 1994; Pretto et al., 2014) . Therefore, we characterized each FXS hiPSC line by determining (i) the number of FMR1 CGG repeats; (ii) the expression of FMR1 mRNA and FMRP; and (iii) the DNA methylation profile of the FMR1 locus. Generally, full mutation FXS is associated with 4200 CGG repeats in the 5'-UTR of FMR1. All FXS hiPSC lines possessed 4200 repeats except line SC128iPS2, which had 150 repeats (Supplementary Table 3 ). Next, we determined the FMR1 expression status for each line. Lines from Patients 105 and 215 did not express either FMRP (encoded by FMR1) or FMR1 transcript (Fig. 1B and C) . Interestingly, although lines SC128iPS5, SC133iPS2, and SC133iPS3 harboured a full mutation allele (250, 210 and 210 repeats, respectively), they all expressed FMR1 mRNA (Fig. 1C) , and low levels of FMRP compared to non-disease lines (Fig. 1B) . These lines, which retain FMR1 expression but are derived from patients diagnosed with FXS and ASD, are referred to as FXS FMR1 + lines. The cell lines included in this study were grouped as: non-disease, FXS FMR1 + , and FXS FMR1À, and are colour-coded as green, grey and black, respectively (Fig. 1A) .
Analysis of DNA methylation patterns at the FMR1 locus demonstrated that, similar to non-disease lines, each of the undifferentiated FXS FMR1 + lines lacked DNA methylation (i.e. were hypomethylated), whereas the FXS FMR1À lines had a hypermethylated signature at the FMR1 locus (Fig. 1B) . Importantly, FXS FMR1 + lines remained hypomethylated and did not silence the FMR1 locus during differentiation to NPCs. Conversely, FXS FMR1À lines remained hypermethylated and the FMR1 locus remained silenced during differentiation (Fig. 1B) . These data show that the DNA methylation status at the FMR1 locus was faithfully maintained during differentiation and DNA methylation of FMR1 was negatively correlated with expression of the gene.
Neurogenic defects of FXS FMR1À human induced pluripotent stem cells
One of the brain regions affected in FXS and ASD is the cortex. Monolayer differentiation of hPSCs by dual SMAD inhibition has been shown to mimic endogenous corticogenesis (Chambers et al., 2009; Shi et al., 2012) . Therefore, we used monolayer dual SMAD inhibition for neuronal differentiation (Supplementary Fig. 2B ). As expected, by Day 12 of differentiation, all hPSC lines primarily generated NPCs (PAX6 + , NESTIN + ) as well as a smaller population of early neural crest derivatives that expressed TFAP2 (Supplementary Fig. 2C ). Furthermore, in agreement with our immunocytochemistry results, Day 12 cell populations highly expressed genes consistent with neuroepithelial or early radial glial cells (PAX6, NES, LHX2, HES5), and to a lesser extent genes indicative of early neural crest (B3GAT1, TFAP2A, NGFR). At this time point we observed low to no expression of ventral forebrain genes (ASCL1, DLX1, NKX2-1), or EOMES which marks intermediate progenitors in the developing neocortex ( Supplementary Fig. 2D ).
When characterizing the early stages of neuronal differentiation, we determined that FXS FMR1À lines generated fewer immature neurons [bIII tubulin (Tuj1) + /NESTINÀ) at differentiation Day 12 compared to the FMR1 + hPSC lines (both non-disease and FXS FMR1 + lines) ( Fig. 2A  and B ). In addition, early neurons generated by the FXS FMR1À lines possessed longer primary neurites relative to immature neurons from FMR1 + hPSC lines ( Fig. 2A and C) . Interestingly, the number of bIII tubulin + immature neurons was no longer significantly different at differentiation Day 15, suggesting a slight neurodevelopmental delay in the FXS FMR1À lines ( Supplementary  Fig. 3 ).
Synaptic network defects in FXS FMR1À neurons
Because of the line-to-line reproducibility observed during the early stages of differentiation, we differentiated one cell line from each group for 85 days, and collected samples for gene expression profiling on differentiation Days 50, 65, and 80 (see below). At these later time points, all neurons expressed the dendritic marker, MAP2, as well as synaptic markers, and gene expression profiles were similar among non-disease, FXS FMR1 + and FXS FMR1À lines ( Supplementary Fig. 4A and B) . As expected, gene expression profiling suggested that the primary neuronal subtype produced was neocortical glutamatergic neurons ( Supplementary Fig. 4B ).
To determine whether hiPSC-derived neurons exhibit properties similar to mature cortical neurons, we performed current and voltage clamp experiments under whole-cell conditions on Day 85 FXS FMR1 + and FMR1À neurons. All neurons displayed mature resting membrane potentials and over half of the neurons from each group tested showed voltage responses similar to those of mature cortical neurons. (Supplementary Fig. 4C and D) . Resting input resistance was high in both groups, often exceeding 1.3 GV, which indicated a low level of voltage-gated membrane conductance activated at or below the resting membrane potential (Supplementary Fig. 4E ). Consistent with high input resistance, regular firing type cells had a low rheobase (Supplementary Fig. 4F ). FXS FMR1 + neurons exhibited abundant excitatory postsynaptic potentials (EPSPs) suggesting the presence of excitatory chemical synapses. Also, voltage clamp recordings revealed excitatory postsynaptic current transients ranging from 3 to 100 pA in amplitude (Supplementary Fig. 4G ). FXS FMR1 + cells intermittently received bursts of EPSPs as well as a few inhibitory postsynaptic potentials. In contrast, FXS FMR1À neurons received significantly less synaptic input and virtually no inhibitory input ( Supplementary Fig.  4H ). The average frequency of synaptic inputs of FXS FMR1À cells was only 17% of that of FXS FMR1 + neurons. Together these data suggest that, at this early developmental stage, neurons derived from FXS FMR1 + hiPSCs formed networks with robust synaptic connectivity, while FXS FMR1À neurons had more immature synaptic networks by comparison. This conclusion is consistent with an analysis of FXS hESCs (Telias et al., 2015) , which further confirms that our FMR1À neurons possess identifiable FXS phenotypes.
Modelling molecular dynamics in the neuronal differentiation of FXS human induced pluripotent stem cells
To identify epigenetic and transcriptomic aberrations during neuronal differentiation of FXS hiPSCs, we generated global DNA methylation and gene expression data from biological replicates of multiple non-disease, FXS FMR1 + , and FXS FMR1À lines at differentiation Days 0, 3, 6, 9, and 12 of cortical differentiation. Additionally, replicate gene expression data were generated at differentiation Days 50, 65, and 80 from one cell line from each of these groups (Supplementary Fig. 1 ). Using these data, our goal was to identify dynamic processes that were involved in neuronal differentiation irrespective of FXS, as well as those having patterns attributable to FXS. We reasoned that many of the molecular dynamics during neuronal differentiation would be maintained between FXS and nondisease cell lines and that these 'normal' processes would provide context to better understand how aberrations specific to FXS may affect biological processes at a network level. In a cursory analysis of global DNA methylation patterns, we observed that FXS FMR1 + lines in some ways resembled non-disease lines, and in other ways resembled FXS FMR1À lines (data not shown). The shared aberrations of FXS FMR1 + cells and FXS FMR1À cells may be associated with trinucleotide repeat expansion or some other unidentified aspect of FXS, while similarities shared between FXS FMR1 + lines and non-disease lines may derive from retention of FMRP expression. For these reasons, we set up statistical tests to identify FXS aberrations that were either associated with loss of FMR1 expression (FXS FMR1À), or with trinucleotide repeat expansion (FXS FMR1À and FXS FMR1 + ).
Gene expression analysis indicates deficits in FXS neuronal maturation and cell migration
In a set of tests (Contrasts 1-3) we compared successive stages of differentiation independently for non-disease cell lines, FXS FMR1À cell lines, and all FXS cell lines (FXS FMR1À and FXS FMR1 + ). The expression of these genes changed significantly during differentiation (fold-change 5 2.0, FDR adjusted P 5 0.05), but not in a manner that was directly attributable to FXS. A second set of comparisons identified genes having dynamic gene expression patterns that were attributable to FXS via loss of FMR1 expression (Contrast 4) as well as trinucleotide repeat expansion (Contrast 5). In a final set of comparisons, we identified genes with static differences between non-disease lines and FXS FMR1À lines (Contrast 6), and between non-disease and all FXS lines (Contrast 7). In total, we identified 4748 genes in these analyses, of which 1403 genes were significantly different in Contrasts 4-7 (fold-change 5 1.5, FDR adjusted P 5 0.05) and were identified as FXS candidates. Figure 3A and B show temporal heat maps of the top 50 most significantly aberrantly up-and downregulated genes in FXS FMR1À cells (relative to non-disease), respectively. Refer to Supplementary Table 5B, for complete searchable differentially expressed gene lists.
Among the dysregulated genes are genes that suggest that FXS FMR1À cells possess defects in signalling (WNT: BAMBI, CPZ, DKK1; and BMP: BMP7, RGMB) as well as defects in cell migration (CHCHD2, BAMBI), cell adhesion (CDH7, CDH12), extracellular matrix (FBLN1) and cytoskeletal (KATNAL2) reorganization, and neuronal maturation (UNC5A). CHCHD2 was originally identified in a screen for migration defects (Seo et al., 2010) and is downregulated or mutated in other neuropsychiatric disorders (Feyeux et al., 2012; Funayama et al., 2015) . BAMBI stimulates WNT signalling by inhibiting TGFb and activin signalling, and is involved in cell migration and metastasis (Onichtchouk et al., 1999; Fritzmann et al., 2009; McLennan et al., 2015) . Together, these data suggest that FXS FMR1À cells have defects in developmental signalling, cell migration, and extracellular matrix (ECM) remodelling. Notably, members of the SLITRK gene family were dysregulated at both early and later stages of differentiation; SLITRK4 was down-regulated in FXS FMR1À NPCs but not neurons, whereas SLITRK2 was downregulated in FXS FMR1À neurons but not NPCs (Fig. 3B) . SLITRK proteins have been reported to suppress neurite outgrowth (Aruga and Mikoshiba, 2003) , which may help explain the aberrant/ precocious neurite outgrowth observed at differentiation Day 12 in the FXS FMR1À lines (Fig. 2) .
To determine whether any of the FXS candidate genes have been implicated in ASD, we compared our FXS candidate gene list to the extensively curated list of ASD-associated genes from the Simons Foundation for Autism Research Initiative (SFARI). We found that 6.27% of FXS candidates were associated with ASD (88 of 1403) (Fig. 3A, B and Supplementary Table 5 ). Furthermore, 110 FXS candidates were previously identified as mRNA targets of FMRP (Darnell et al., 2011) . FXS candidate genes were significantly enriched for both FMRP target genes (P = 3.15 Â 10
À11
) and SFARI genes (P = 2.03 Â 10 À4 ) (Fig. 3C ). Annotated lists of SFARI genes can be found in Supplementary Table 4A and B, respectively.
Gene network analysis
We used WGCNA to identify gene sets that coordinately varied during the course of neuronal differentiation. See Supplementary Table 5B , for complete, searchable gene expression WGCNA results. Eleven covariant gene modules were associated with the temporal progression of neuronal differentiation (GEX-Purple-Turquoise) and one module was associated with FXS-disease status (GEX-Grey module) (Fig. 4A) . Chi-square tests were performed to determine whether any of the modules were enriched for FXS candidates. GEX-modules associated with undifferentiated pluripotent stem cells (differentiation Day 0) (Green), NPCs (differentiation Days 6-12) (Pink, Magenta, Black), neurons (differentiation Days 50-80) (Turquoise) and FXS-disease status (Grey) were all enriched for FXS candidates (Fig. 4B) . Interestingly, GEX-Purple, which was strongly correlated with differentiation Day 0, was rapidly downregulated during NPC specification and then upregulated at later stages of differentiation (differentiation Days 50-80), was also enriched for FXS candidates.
The Genomic Regions Enrichment Annotation Tool (GREAT) (McLean et al., 2010) was used to assign function to the list of FXS candidates and the GEX-modules identified by WGCNA (Fig. 4C ). Refer to Supplementary  Table 5B and D, for complete, searchable information regarding GEX WGCNA and GREAT enrichments, respectively. The three most highly significant gene ontology (GO) terms among the FXS candidate genes were associated with neuron projection development and morphogenesis, and axon development (Fig. 4C) . Undifferentiated PSCs (differentiation Day 0) and differentiation Day 3 cells were strongly correlated with gene sets involved in various metabolic processes, brain development, and mitosis (GreenPink modules). On Days 6 and 9 of differentiation, genes involved in mitosis, microtubule cytoskeletal organization, WNT-signalling, and the actin cytoskeleton were upregulated (Blue -Yellow modules). On Days 9 and 12 of differentiation, GEX-modules Brown and Black predominated, which contain genes involved in extracellular matrix reorganization, locomotion, and organogenesis. The Turquoise module (correlated with the later stages of neuronal differentiation) (Fig. 4A) , was composed of genes regulating axonogenesis, polarized growth, growth cone establishment, synaptic vesicles, and membrane transporters (Fig. 4C) .
Among the candidates enriched in NPCs (differentiation Days 0-12) and neurons (differentiation Days 50-80) were a number of neural transcription factors (FEZF1, HHEX, NEUROG2, SIX3, METRNL), cell adhesion molecules (CD9, FBLN1, VCAM1, PCDH7), genes associated with signalling during CNS development (TDGF1, NQO2, GPR78, GPR98, SPRY1, DKK1, C8orf4, ARRB1), ECM/ cytoskeletal remodelling (KATNAL2, TGLN, FABP7, LEPREL1, KANK4), and axon guidance (FABP7, RGMB, UNC5A). Furthermore, the neuron-specific GEX-Turquoise module contained a greater proportion of FXS candidates relative to the NPC-associated Magenta and Black modules (Fig. 4B) . Together, these results suggest that the dysregulation of gene expression in our FXS hiPSC model begins during the specification of dorsal forebrain NPCs and is further enhanced in differentiated neurons.
Aberrant DNA methylation patterns in FXS cells
Profound changes to global genomic methylation patterns occur during the early stages of hPSC differentiation (Nazor et al., 2012) . The FMR1 epigenetic silencing that occurs in FXS prompted us to ask whether this heterochromatin event had only localized effects on the X chromosome or might perturb DNA methylation patterns on a more global scale. We profiled global DNA methylation patterns in non-disease, FXS FMR1 + and FXS FMR1À cells at Days 0, 3, 6, 9, and 12 of neuronal differentiation. Using statistical analyses similar to those used to identify dysregulated genes, we identified 4640 DMCs that either gained or lost methylation during differentiation, 1603 of which were specific to FXS cells and are referred to as FXS candidate DMCs, (Supplementary Table 5C ). Both gains and losses of methylation were observed in FXS FMR1À lines relative to non-disease lines (Fig. 5A ). As discussed above, there were methylation patterns shared by both types of FXS cells (FMR1 + and FMR1À) that differed from non-disease cells, and at some loci FXS FMR1 + cells exhibited an intermediate global methylation pattern compared to non-disease and FXS FMR1À cells (Fig. 5A) .
We also observed both DNA hypomethylation and hypermethylation that was specific to FXS FMR1À cell lines. Surprisingly, only 5.6% (90 of 1603) of candidate DMCs occurred on the X chromosome, while the vast majority (93.9%, 1506 of 1603) were located on autosomes; this demonstrates that DNA methylation abnormalities in FXS FMR1À cells are not restricted to the X chromosome. Not surprisingly, candidate DMCs found on the X chromosome were located at, or near, the FMR1 locus (Supplementary  Table 5C ). Finally, we assessed DMC enrichment in relation to CpG density by determining whether they were preferentially enriched in CpG islands (CGI), shores or shelfs (Fig. 5B) . Chi square distribution showed non-candidate DMCs were significantly enriched in areas of low CpG density whereas candidate DMCs exhibited a bias toward regions of increased CpG density, and were particularity enriched in CpG islands over shores and shelfs (island 4 shore 4 shelf) (Fig. 5C) .
We also performed WGCNA on the methylation data, which identified 15 covariant sets of DMCs associated with differentiation or FXS disease state (see 'Materials and methods' section, Fig. 6A and Supplementary Table  5C ). Among these were strongly correlated sets of cytosines that were highly methylated in undifferentiated hPSCs, which progressively lost methylation over time ( Fig. 6A ; DMC-Blue, Pink, Magenta modules). GREAT analysis indicated that these modules contained functional enrichments related to cell proliferation and developmental signalling involved in neuralization ( Fig. 6C and Supplementary  Table 5E ). Conversely, the DMCs of the Green module were unmethylated in hPSCs, gained methylation beginning at differentiated Day 6, and were associated with genes involved in forebrain development and regionalization (Fig. 6C) . Nine modules (DMC-Grey -Purple) were robustly correlated with disease state (Fig. 6A) . Methylation within many of these modules exhibited an inverse pattern in non-disease lines relative to FXS FMR1À lines. For example, modules containing methylated DMCs in FXS FMR1À cells lacked methylation in non-disease cells (DMC-Grey60 -Purple) and vice versa (DMC-GreyCyan). Chi square distribution demonstrated that FXS candidate DMCs were enriched within modules associated with disease state rather than day of differentiation (Fig.  6B) . The majority of the cell group-specific modules lacked GREAT functional enrichments; however, modules DMCGrey, Black, Grey60, and Midnightblue were all significantly enriched for the GO terms 'MHC class II protein complex' and 'integral to luminal side of endoplasmic reticulum membrane' (Fig. 6C) .
Integrated analyses identify epigenetic-mediated dysregulation of gene expression in FXS
We performed several analyses in order to examine whether methylation dynamics of candidate DMCs affects FXS candidate gene expression. First, we calculated Pearson correlations for all significant DNA methylation and gene expression probes that could be associated using GREAT. The distribution of correlation values among all DMCs and gene expression showed a trimodal distribution, wherein DMCs were either positively correlated, negatively correlated, or weakly correlated with expression (Fig. 7A) . Replotting the distribution of correlation values for all DMCs according to CpG island proximity showed that DMCs in regions with high CpG density had less of an effect on gene expression compared to those in with low CpG density (Fig. 7B) .
We filtered the set of associated DNA methylation and gene expression probes by identifying those beyond the inflection points in the trimodal distribution. Therein, we identified 824 genes that met significance criteria in the analysis of both gene expression and DNA methylation (Supplementary Table 6 ), of which 32 genes were independently identified as FXS candidates according to patterned gene expression and DNA methylation ( Table  1) . Three of these genes are FMRP targets (RIMBP2, PEG3, MYT1L) and four are SFARI genes (DPP6, GAP43, HLA-DRB1, MYT1L). Interestingly, five of these genes, CHCHD2, ERC1, MYOM2, HLA-DRB5, COL22A1 (Table 1) , exhibited both positive and negative correlation with expression indicating cyclical expression during differentiation. Also, it should be noted that two of the genes (PEG3, NNAT) are paternally-expressed imprinted genes that are known to exhibit highly variable methylation patterns across hPSC lines (Nazor et al., 2012) .
Discussion
We have identified a differential gene expression profile in FXS FMR1À cells relative to FXS FMR1 + and non-disease cells. Several of these genes were constitutively dysregulated throughout differentiation, implicating the encoded protein FMRP in the regulation of their expression. Furthermore, aberrant expression of genes such as BAMBI, BMP7, DKK1, and TDGBI (among others) indicated abnormal developmental signalling on loss of FMRP.
During embryogenesis, the timing of developmental events is crucial to normal development. We observed delayed neurodevelopment in our FXS FMR1À lines, in agreement with studies of differentiation of FXS hESCs (Telias et al., 2013) . Aberrant signalling during differentiation and/or cell migration defects may cause or contribute to this phenotype. It is also possible that the dual SMAD differentiation conditions used here may amplify otherwise subtle FXS FMR1À phenotypes. Our results point to temporal defects in ECM and actin/ cytoskeletal remodelling, implicating defective migration in human FMR1À cells. Defective cell migration has recently become a recognized abnormality in a number of neuropsychiatric disorders, including ASD, epilepsy, and schizophrenia (Pinto et al., 2010; Peñ agarikano et al., 2011; Brennand et al., 2015) . Moreover, studies have shown that neuronal progenitor cells of Fmr1 knockout mice exhibit aberrant migration and differentiation (Castren et al., 2005; Tervonen et al., 2009; Saffary and Xie, 2011) .
In contrast to a recent report that examined neurons derived from FXS hiPSCs (Doers et al., 2014) , we observed enhanced neurite lengthening in the first immature FXS FMR1À neurons born relative to neurons derived from hPSCs expressing FMR1. Apparent discrepancies between these studies are likely attributable to the age of the neurons examined [early (this study) versus relatively mature (Doers et al., 2014) ]. Enhanced neurite extension in our early FXS FMR1À neurons is potentially attributable to downregulation of SLITRK4 during NPC differentiation, a finding indirectly supported by studies in the mouse that show that loss of FMRP results in enhanced growth cone extension and reduced motility (Antar et al., 2006; Li et al., 2009) . Furthermore, Benvenisty and colleagues have recently shown dysregulated expression of ROBO, SLIT, and REST targets genes in neurons derived from FXS hiPSCs . We identified dysregulation of ROBO (ROBO2), SLIT (SLITRK2 and 4) and the REST target, TSPAN7, all of which regulate axon guidance, neurite extension and cell motility. Additionally, our data show that several regulators of axon guidance and/or neurite length (SPAST, RGMB, SEMA3C, SLITRK2) are downregulated in FXS FMR1À neurons, suggesting that delayed neuronal/synaptic maturation may contribute to the reduced synaptic activity we observed in late stage (D85) FXS FMR1À neurons.
Recently, FMRP has been associated with epigenetic regulation (i.e. nucleosome remodelling and post-translational histone methylation) (Parikshak et al., 2013) . Aberrant DNA methylation patterns at CpG-dense regions in FXS FMR1À cells suggests that FMRP may play a role (either directly or indirectly) in the regulation of DNA methylation at specific genomic sequences. Our integrative analysis also provides evidence that, in the absence of FMRP, aberrant DNA methylation patterns affect gene expression during differentiation. To our knowledge this is a novel, but not entirely unexpected, feature of FMRP given the large number of genes it regulates. While we did not pinpoint the exact role of FMRP in epigenetic or transcriptional regulation, this function is likely mediated via modulation of the expression of epigenetic regulators, and it is intriguing that this may occur in a cell type-specific manner during brain development.
Interestingly, we observed a constitutive downregulation of AZIN1 expression in all FXS FMR1À cells relative to non-disease. AZIN1 (antizyme inhibitor 1) is involved in the regulation of polyamine biosynthesis, which has been shown to have effects on DNA methylation in embryoniclike cells (Heby, 1995; Frostesjo et al., 1997) . While a link between polyamine levels and FXS remains uninvestigated, aberrant polyamine synthesis has been attributed to SnyderRobinson syndrome; an X-linked disorder also characterized by facial abnormalities, delayed development and intellectual disability (Lauren Cason et al., 2003; de Alencastro et al., 2008) .
The results reported here contribute to a more detailed understanding of events underlying neuronal dysfunction in FXS and ASD. Specifically, they indicate that gene expression and DNA methylation patterns begin to show abnormalities very early during neurogenesis. It will be interesting to determine whether these characteristics are shared by multiple neurodevelopmental diseases, which would provide insight into common interventions that might mitigate the neuropathology in these diseases.
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